Ariad V. Lilly

Ariad V. Lilly

Ariad Pharmaceuticals et al. v. Eli Lilly and Company is a United States court case regarding accusations of infringement by Eli Lilly on U.S. Patent 6,410,516 held by ARIAD Pharmaceuticals. The Federal Circuit ruled en banc to invalidate the patent for a lack of sufficient description of the invention. Amici briefing before the en banc panel was intensive, with 26 separate briefs filed, and the final decision has been heavily discussed by legal commentators. Its ultimate impact on biotechnology patents remains to be determined.

Read more about Ariad V. Lilly:  The '516 Patent At Issue, Federal Circuit Three-member Panel Appellate Ruling For Eli Lilly, Federal Circuit's En Banc Hearing Again Holds For Eli Lilly